Fears about flattening Opdivo sales were surely a major driver for Bristol's move for Celgene. To keep growing the checkpoint inhibitor needs some big clinical wins.
Scholar Rock selects a lead molecule inhibiting TGF-β, an increasingly important oncology mechanism that Glaxosmithkline recently paid €300m to enter.
Others hoping to get FDA approvals include Sage Therapeutics and Novartis, but hopes look dimmer for Lexicon and Sanofi.
Until now all PD-(L)1 blockers were assumed to have broadly similar activity, with any differences being put down to trial design; the latest renal cancer data could…
In the Keynote-426 study Merck & Co’s Keytruda looks to have blasted Opdivo out of the water, showing a 47% reduction in risk of death versus Sutent.
Merck & Co awaits full Keynote-426 data with Keytruda plus Inlyta, while Seattle Genetics looks beyond Adcetris with enfortumab vedotin.
The French company has taken a look at its R&D portfolio, and made some radical changes in oncology and diabetes.
As Glaxosmithkline manoeuvres to become a major player in cancer, it backs Icos among other novel mechanisms.